Reflections about the efficiency criteria for cancer treatments during marketing authorization application

Réflexions sur les critères d’évaluation des traitements anticancéreux lors des procédures d’autorisation de mise sur le marché

N. Jeannin, S. Blois-da Conceicao () and Christel Protière
Additional contact information
N. Jeannin: SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale
S. Blois-da Conceicao: SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale, Institut de Psychologie - UL2 - Université Lumière - Lyon 2

Post-Print from HAL

Abstract: Although clear and validated recommendations exist concerning the evaluation of cancer treatments at the international level, the criteria retained to obtain the marketing authorization (MA) are multiple and heterogeneous. This qualitative survey explores the opinion related to the assessment of cancer treatment among the several concerned population. By the way of semi-structured interviews, our aim was to elicit perceptions toward the criteria which should be retained during the process of MA, by patients, oncologists, members of the pharmaceutical industry, health decision-makers and general population. Our survey emphasizes the variability of the significations associated with the criteria of efficiency of cancer treatments according to the characteristics of the respondents. We also have observed some common expectations from patients and oncologists toward the economic and political aspect, but also from the whole respondents toward the importance of the comfort of the patients. Lastly, the necessity to define specific criteria related to clinical cases emerges.

Keywords: Cancer treatments; Marketing authorization; Representations; Quality of life; Length of life; Traitements anticancéreux; Autorisation de mise sur le marché; Représentations; Qualité de vie; Durée de vie (search for similar items in EconPapers)
Date: 2013-03
References: Add references at CitEc
Citations:

Published in Bulletin du Cancer, 2013, 100 (3), pp.259-269

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01799676

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().